Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Cancer

    • Home
    • Cancer
    • Page 146
Company Drug

Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study

Fineline Cube May 14, 2020

Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...

Company Drug

Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients

Fineline Cube May 14, 2020

Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...

Posts pagination

1 … 145 146

Recent updates

  • Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs
  • Sichuan Biokin Receives NMPA Go-Ahead for SI-B036 Bispecific Antibody Clinical Study in Advanced Solid Tumors
  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for SI-B036 Bispecific Antibody Clinical Study in Advanced Solid Tumors

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.